A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide
Cancer Research and Treatment. 2019;51(2):812-818 
Toxicity of Dose-Dense Docetaxel Followed by Doxorubicin with Cyclophosphamide as Adjuvant Therapy for Breast Cancer in a Phase II Study
Clinical Breast Cancer. 2007;7(9):697-704
Randomized Phase II Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin Plus Cyclophosphamide in Axillary Node-Positive Breast Cancer
Breast Diseases: A Year Book Quarterly. 2009;20(2):198-199
Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer
Breast Cancer Research and Treatment. 2011;130(3):825-831
Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study
Breast Cancer Research and Treatment. 2010;125(1):115-120
Randomized phase II trial of high-dose 4′-epi-doxorubicin + cyclophosphamide versus high-dose 4′-epi-doxorubicin + cisplatin in previously untreated patients with extensive small cell lung cancer
Lung Cancer. 1993;10(1-2):147
Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel (Dose Dense AC Followed by T) Regimen for Breast Cancer
Hospital Pharmacy. 2005;40(4):310-314
Efficacy of same-day versus next-day administration of pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide: A retrospective multi-site analysis
Journal of Oncology Pharmacy Practice. 2022;107815522211481
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group
Annals of Oncology. 2012;23(2):331-337
Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer
Breast Cancer Research and Treatment. 2005;97(3):311-318